Summary & Overview
HCPCS C9155: Injection of epcoritamab-bysp, 0.16 mg
HCPCS Level II code C9155 designates a 0.16 mg unit of epcoritamab-bysp for injection, a targeted monoclonal antibody used in oncology care. As a drug administration code, it matters nationally because accurate unit-level coding supports clinical documentation, pharmacy accounting, and payer adjudication for high-cost specialty therapies administered in outpatient and infusion settings. Precise coding for agents like epcoritamab-bysp affects drug utilization tracking, claims processing, and patient cost-sharing calculations.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical intent and service context, a review of payer coverage considerations, common billing modifiers, and pointers to related billing elements. The publication summarizes national benchmarks for specialty drug administration where available, highlights common documentation elements needed for claims, and notes policy update channels that typically affect reimbursement and prior authorization for oncology biologics.
This content is intended for billing professionals, revenue cycle leaders, and clinical administrators seeking a clear, national-level primer on how C9155 is used in practice and what to monitor for payer interactions and operational workflows.
Billing Code Overview
HCPCS Level II code C9155 describes an injection of epcoritamab-bysp, 0.16 mg. This entry represents a specific dosage unit for the monoclonal antibody therapy epcoritamab-bysp, intended for parenteral administration.
-
Service type: Injection, drug administration
-
Typical site of service: Ambulatory infusion center or outpatient oncology clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory B‑cell non‑Hodgkin lymphoma (for example, diffuse large B‑cell lymphoma) who is being treated with subcutaneous bispecific antibody therapy. The patient presents to an outpatient oncology infusion clinic for administration of C9155 (epcoritamab‑bysp) measured per 0.16 mg units. Clinical workflow: registration and verification of diagnosis and prior authorization; nursing assessment including vitals and cytokine release syndrome (CRS) risk screening; premedication per institutional protocol (antipyretic, antihistamine, corticosteroid as indicated); preparation of the drug by pharmacy using the prescribed dose converted into 0.16 mg units; administration via subcutaneous injection in the clinic with monitoring for immediate adverse reactions for a period defined by the immunotherapy protocol (often several hours during initial doses); documentation of lot numbers, injection site, dose in 0.16 mg units, and any reactions; discharge instructions and scheduling of follow‑up or subsequent doses. Typical site of service is an outpatient oncology infusion clinic or physician office experienced in subcutaneous immunotherapy delivery.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|